Example: Heart Attack

Clinical Trials on Mucopolysaccharidosis Type I

Total 68 results

NCT03580083

Recruiting

RGX-111 Gene Therapy in Patients With MPS I

Conditions: Mucopolysaccharidosis Type I (MPS I)
NCT03576729

Completed

MRS to Determine Neuroinflammation and Oxidative Stress in MPS I

Conditions: Mucopolysaccharidosis Type I
NCT04453085

Not yet recruiting

An Extension Study of JR-171-101 Study in Patients With MPS I

Conditions: Mucopolysaccharidosis I
NCT04227600

Recruiting

A Study of JR-171 in Patients With Mucopolysaccharidosis I

Conditions: Mucopolysaccharidosis I
NCT02437253

Completed

Effects of Adalimumab in Mucopolysaccharidosis Types I, II and VI

Conditions: Mucopolysaccharidosis Type I; Mucopolysaccharidosis Type II; Mucopolysaccharidosis Type VI
NCT03071341

Completed

Extension Study Evaluating Long Term Safety and Activity of AGT-181 in Children With MPS I

Conditions: Mucopolysaccharidosis I
NCT03053089

Completed

Safety and Dose Ranging Study of Human Insulin Receptor MAb-IDUA Fusion Protein in Adults and Children With MPS I

Conditions: Mucopolysaccharidosis I
NCT02371226

Unknown status

Safety and Dose Ranging Study of Insulin Receptor MAb-IDUA Fusion Protein in Patients With MPS I

Conditions: Mucopolysaccharidosis I
NCT02702115

Active, not recruiting

Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-318 in Subjects With MPS I

Conditions: MPS I
NCT03153319

Recruiting

Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I and II

Conditions: Mucopolysaccharidosis I; Mucopolysaccharidosis II
NCT00144794

Recruiting

Mucopolysaccharidosis I (MPS I) Registry

Conditions: Mucopolysaccharidosis I (MPS I)
NCT03161171

Completed

Parental Coping With Challenging Behavior in Mucopolysaccharidosis Type I-III

Conditions: Mucopolysaccharidosis Type I; Mucopolysaccharidosis Type II; Mucopolysaccharidosis Type III; Behavior Disorders; Coping Behavior
NCT00741338

Completed

Immune Tolerance Study With Aldurazyme® (Laronidase)

Conditions: Mucopolysaccharidosis I
NCT02232477

Terminated

Extension Study of Intrathecal Enzyme Replacement for Cognitive Decline in MPS I

Conditions: Mucopolysaccharidosis I; Cognitive Decline
NCT03488394

Active, not recruiting

Gene Therapy With Modified Autologous Hematopoietic Stem Cells for the Treatment of Patients With Mucopolysaccharidosis Type I, Hurler Variant

Conditions: Mucopolysaccharidosis IH
NCT00258011

Completed

Study of Aldurazyme® Replacement Therapy in Patients With Mucopolysaccharidosis I (MPS I) Disease

Conditions: Mucopolysaccharidosis I; Hurler Syndrome; Hurler-Scheie Syndrome; Scheie Syndrome
NCT00748969

Terminated

Clinical Trial of Growth Hormone in MPS I, II, and VI

Conditions: Mucopolysaccharidosis I; Mucopolysaccharidosis II; Mucopolysaccharidosis VI
NCT00146770

Completed

Phase 3 Extension Study of the Safety and Efficacy of Aldurazyme® (Laronidase) in Mucopolysaccharidosis I (MPS I) Patients

Conditions: Mucopolysaccharidosis I; Hurler's Syndrome; Hurler-Scheie Syndrome; Scheie Syndrome
NCT00144781

Completed

A Dose-optimization Study of Aldurazyme® (Laronidase) in Patients With Mucopolysaccharidosis I (MPS I) Disease

Conditions: Mucopolysaccharidosis I; Hurler's Syndrome; Hurler-Scheie Syndrome; Scheie Syndrome
NCT00418821

Unknown status

A Study of the Effect of Aldurazyme® (Laronidase) Treatment on Lactation in Female Patients With Mucopolysaccharidosis I (MPS I) and Their Breastfed Infants

Conditions: Mucopolysaccharidosis I; Hurler's Syndrome; Hurler-Scheie Syndrome; Scheie
NCT00146757

Completed

A Study Evaluating the Safety and Pharmacokinetics of Aldurazyme® (Laronidase) in MPS I Patients Less Than 5 Years Old

Conditions: Mucopolysaccharidosis I; Hurler Syndrome; Hurler-Scheie Syndrome; Scheie Syndrome
NCT02597114

Completed

Extension Study of AGT-181-102 to Evaluate Long Term Safety and Activity of AGT-181

Conditions: Mucopolysaccharidosis I
NCT00852358

Completed

A Study of Intrathecal Enzyme Therapy for Cognitive Decline in MPS I

Conditions: Cognitive Decline; Mucopolysaccharidosis I; Hurler-Scheie Syndrome; Scheie Syndrome; Lysosomal Storage Disease
NCT00786968

Terminated

Extension Study of Intrathecal Enzyme Replacement Therapy for MPS I

Conditions: Spinal Cord Compression; Mucopolysaccharidosis I; Hurler-Scheie Syndrome; Scheie Syndrome; Lysosomal Storage Disease
NCT00912925

Completed

Clinical Study of Aldurazyme in Patients With Mucopolysaccharidosis (MPS) I

Conditions: Mucopolysaccharidosis I; Hurlers Syndrome; Hurler-Scheie Syndrome